Altasciences and WuXi AppTec Enter Into Collaboration for WIND Projects

LAVAL, Quebec–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Altasciences?src=hash" target="_blank"gt;#Altascienceslt;/agt;–Altasciences, a mid-size CRO specializing in a flexible, innovative
approach to providing comprehensive early stage drug development from
lead candidate selection to proof of concept, announced today that they
have entered into an agreement to support WuXi AppTec’s Investigational
New Drug (WIND) platform. WIND combines world-class CRO services with
cross-functional program management and global regulatory expertise to
support IND applications. WuXi Clinical, the clinical CRO arm of WuXi
AppTec, will be responsible for managing the partnership and ensuring a
seamless experience.

Altasciences will provide its full-service solutions, including clinical
pharmacology, first-in-human and proof-of-concept trials, program
management, medical writing, biostatistics, and data management to
support and conduct comprehensive early phase clinical services for WuXi
AppTec’s multiple ongoing WIND programs.

“WuXi AppTec and Altasciences share the same vision, which is to
provide a seamless, integrated transition from one key milestone to the
next during the early phases of drug development. I am confident that
together, we will continue on our path to help sponsors research and
develop potentially life-saving therapeutics, faster,” stated Chris
Perkin, CEO, Altasciences.

With integrated capabilities in toxicology, DMPK, pharmacology, CMC, and
analytical services, WuXi AppTec supports the full scope of drug
development programs, from IND-enabling studies to regulatory support
for both pre-IND and post-IND stages, as well as document preparation
and submission.

“Altasciences has strong expertise and deep experience in
early phase clinical research. The partnership is an excellent
complement for WuXi to help our global collaborators to expedite the R&D
process from pre-IND to clinical stages and bring better therapies to
patients far faster,” said Edward Hu, Co-CEO, WuXi AppTec.

About Altasciences
Altasciences is
a forward-thinking, mid-size contract research organization
offering pharmaceutical and biotechnology companies of all sizes a
proven, flexible approach to preclinical and early phase clinical
studies, from lead candidate selection to proof of concept. For over 25
years, Altasciences has been integrating into clients’ projects to help
support educated, faster, and more complete early drug development
decisions. Altasciences’ full-service solutions include preclinical
safety testing, clinical pharmacology, bioanalysis, program management,
medical writing, biostatistics, and data management, all of which can be
tailored to specific sponsor requirements. Altasciences… helping
sponsors get better drugs to the people who need them, faster.

About WuXi AppTec
WuXi
AppTec is a leading pharmaceutical and medical device open-access
capability and technology platform company with global operations. As an
innovation-driven and customer-focused company, WuXi AppTec provides a
broad and integrated portfolio of services to help our customers and
partners worldwide shorten the discovery and development time and lower
the cost of drug and medical device R&D through cost-effective and
efficient solutions. With its industry-leading capabilities such as
small molecule R&D and manufacturing, cell therapy and gene therapy R&D
and manufacturing, and medical device testing, the WuXi platform is
enabling more than 3,500 innovative collaborators from more than 30
countries to bring innovative healthcare products to patients, and to
fulfill WuXi’s dream that “every drug can be made and every disease can
be treated.”

Contacts

Julie-Ann Cabana
Altasciences
913 304-4505
[email protected]